Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified fixed-dose Aflibercept 8 mg in treatment-naïve nAMD
ChiCTR2600129035Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by Tianjin Medical University Eye Hospital. Primary endpoint: Aqueous humor VEGF-A at 12 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2600129035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129035.